Chirag Chauhan, MD
Interventional Cardiology · Boulder, CONPI 1437313376
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 56.5% of the total. Reporting peaked in 2023 at $9,051 and has fallen 69.7% since, to $2,738 in 2025.
Across 481 payments — averaging $73.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Abiomed$4K
- Penumbra, Inc.$2K
- Abbott$2K
- Edwards Lifesciences$2K
- Boston Scientific$830
- plus $3K from 28 others
What the payments were for
- Consulting fees$8,95325%
- Speaking & faculty fees$3,56610%
- Travel & lodging$9,12226%
- Food & beverage$13,66339%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 167 | $19,958 |
| Abiomed | 75 | $4,441 |
| Penumbra, Inc. | 7 | $2,421 |
| Abbott | 44 | $2,273 |
| Edwards Lifesciences | 22 | $2,104 |
| Boston Scientific | 33 | $830 |
| Amgen | 27 | $492 |
| Novartis | 15 | $312 |
| Cvrx, Inc. | 3 | $269 |
| Pfizer | 12 | $251 |
| Cardiovascular Systems Inc. | 5 | $245 |
| Shockwave Medical, Inc | 3 | $213 |
| Siemens Medical Solutions USA, Inc. | 1 | $207 |
| AstraZeneca | 11 | $191 |
| E.r. Squibb & Sons, L.L.C. | 11 | $179 |
| Merck | 9 | $140 |
| Alnylam Pharmaceuticals Inc. | 5 | $105 |
| La Jolla Pharmaceutical Company | 1 | $99 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $81 |
| Boehringer Ingelheim | 5 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $69 |
| Akcea Therapeutics, Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| W. L. Gore & Associates, Inc. | 2 | $37 |
| Chiesi USA, Inc. | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Veryan Medical Incorporated | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Bayer | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$6,677
- Impella$2,534
- Indigo System$2,255
- CoreValve Evolut$1,044
- Mitra Clip system$1,008
- Micra$421
- SYMPLICITY G3$345
- SAPIEN 3 Ultra RESILIA$306
- MitraClip$243
- CorPath GRX$207
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$176
- Barostim Neo System$171
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$160
- Reveal LINQ$151
- Resolute$143
- Edwards SAPIEN 3 Transcatheter Heart Valve$133
- Peripheral Orbital Atherectomy System$131
- WATCHMAN Access System$130
How this compares
$35,317 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $142,700 |
| EntrestoSacubitril/Valsartan | 20 | $32,094 |
| XareltoRivaroxaban | 27 | $24,064 |
| Repatha SureclickEvolocumab | 31 | $22,848 |
| Ranolazine ErRanolazine | 24 | $4,896 |
| ClopidogrelClopidogrel Bisulfate | 147 | $2,001 |
| Atorvastatin Calcium | 186 | $1,978 |
| Metoprolol Succinate | 114 | $1,731 |
| Rosuvastatin Calcium | 158 | $1,519 |
| Carvedilol | 141 | $1,501 |
| Potassium Chloride | 39 | $1,387 |
| Metoprolol Tartrate | 145 | $854 |
| Nifedipine ErNifedipine | 14 | $778 |
| Chlorthalidone | 32 | $709 |
| Losartan Potassium | 116 | $683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $251 | $142,700116 claims |
| NovartisEntresto | $312 | $32,09420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Boulder
- Srinivas IyengarBoulder$254K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
- Qaisar KhanThornton$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.